How to buy Tekmira Pharmaceuticals Corporation stock

Tekmira Pharmaceuticals Corporation is an other business based in the US. Tekmira Pharmaceuticals Corporation shares (TKMR) are listed on the NASDAQ and all prices are listed in US Dollars.

Tekmira Pharmaceuticals Corporation stock price (NASDAQ: TKMR)

Use our graph to track the performance of TKMR stocks over time.

Tekmira Pharmaceuticals Corporation shares at a glance

• Key figures

Information last updated 2020-10-30.

52-week range	$2.79 - $3.05
50-day moving average	$10.83
200-day moving average	$10.83
Wall St. target price	N/A
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Tekmira Pharmaceuticals Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Tekmira Pharmaceuticals Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Tekmira Pharmaceuticals Corporation financials

Gross profit TTM	$0
Return on assets TTM	0%
Return on equity TTM	0%
Profit margin	0%
Book value	N/A
Market capitalisation	$156.2 million

TTM: trailing 12 months

Tekmira Pharmaceuticals Corporation share dividends

We're not expecting Tekmira Pharmaceuticals Corporation to pay a dividend over the next 12 months.

Tekmira Pharmaceuticals Corporation overview

DELISTED - Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (RNA) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical partners. On March 1, 2012, it announced that the Company had secured a license from Alnylam to develop TKMALDH2, an RNAi therapeutic that utilizes Tekmira's LNP for the treatment of Alcohol Dependence (AD). Its lead oncology product candidate, TKM-PLK1, targets PLK1, a protein involved in tumor cell proliferation and a validated oncology target. On February 8, 2012, it announced that Phase I clinical trial for TKM-Ebola had been initiated. The Phase 1 TKM-Ebola clinical trial is a placebo-controlled, single-blind, single-ascending dose study with additional multiple-ascending dose cohorts in healthy human volunteers. In the field of RNAi therapeutics, the Company has licensed its LNP delivery technology to Alnylam Pharmaceuticals, Inc. and Merck & Co.

Frequently asked questions

What is Tekmira Pharmaceuticals Corporation's ISIN number?
Tekmira Pharmaceuticals Corporation's international securities identification number is: US03879J1007 What is Tekmira Pharmaceuticals Corporation's CUSIP number?
Tekmira Pharmaceuticals Corporation's Committee on Uniform Securities Identification Procedures number is: 03879J100